# US 2015/0031832 A1 · Carrier nanoparticles and related compositions, methods and systems

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2015/0031832 A1
- Document ID: US20150031832A1
- Status: Published application
- Kind: A1
- Application number: 14/509,118
- Filed: 2014-10-08
- Published: 2015-01-29
- Earliest claimed: 2008-08-13
- Assignees: California Institute of Technology
- Applicants: California Institute of Technology
- Inventors: MARK E. DAVIS; AKINLEYE ALABI
- Web page: https://patentgrep.com/patent/US20150031832A1

## CPC

- A61K 47/6935: {the polymer being obtained otherwise than by reactions involving carbon to carbon unsaturated bonds, e.g. polyesters, polyamides or polyglycerol}
- A61K 9/14: Particulate form, e.g. powders, {Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles (microspheres A61K9/16; microcapsules A61K9/50; nanocapsules, nanoparticles of the matrix type A61K9/51)}
- A61K 9/5146: {obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides}
- A61K 31/337: having four-membered rings, e.g. taxol
- A61K 31/4745: condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines (yohimbine derivatives, vinblastine A61K31/475; ergoline derivatives A61K31/48)
- A61K 31/704: attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin {(digitoxin A61K31/7048)}
- A61K 31/713: Double-stranded nucleic acids or oligonucleotides
- A61K 47/545: {Heterocyclic compounds (A61K47/558 takes precedence)}
- A61K 47/549: {Sugars, nucleosides, nucleotides or nucleic acids}
- A61K 47/59: obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K 47/595: {Polyamides, e.g. nylon (polyamino acids A61K47/62)}
- A61K 47/60: the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
- A61K 47/62: the modifying agent being a protein, peptide or polyamino acid
- A61K 47/644: {Transferrin, e.g. a lactoferrin or ovotransferrin}
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 35/00: Antineoplastic agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C08G 59/4078: {boron containing compounds}
- C08G 65/337: containing other elements (organic compounds containing halogens only as halides of a carboxyl group C08G65/332)
- C08G 69/40: Polyamides containing oxygen in the form of ether groups (C08G69/12, C08G69/32 take precedence)
- C08G 69/48: Polymers modified by chemical after-treatment
- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- C12N 2310/14: interfering nucleic acids [NA]
- C12N 2310/351: Conjugate
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C08G: MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Carrier nanoparticles comprising a polymer containing a polyol coupled to a polymer containing a boronic acid, configured to present the polymer containing a boronic acid to an environment external to the nanoparticle and related compositions, methods and systems.

## Claims

### Claim 1

A polymer conjugate comprising a boronic acid of formula:
wherein
R3 and R4 are independently (CH2CH2O)t, where t is from 2 to 2000,
X1 is —NH—C(═O)—, —C(═O)—NH—CH2, —C(═O)—NH—, —S—S—, —O—C(═O)— or —C(═O)—O—;
Y1 is an alkylene with a carbon number of at least 1 or is an aromatic group;
Functional group 1 and Functional group 2 are the same or different and independently comprise —OCH3, —OH, —B(OH)2, —COOH, —NH2, or —(X1)—(Y1)—B(OH)2;
r is in a range of from 1 to 1000;
a is 0, 1, 2, or 3; and
b is 1, 2 or 3; and
a polyol polymer having a repeating structure of:
where n is from 1 to 20,
wherein the boronic acid polymer is coupled to the polyol polymer with at least one reversible borate ester linkage that replaces the hydroxyl groups of the Y1—B(OH)2 moiety.

### Claim 2 (depends on 1)

The polymer conjugate of claim 1, wherein Y1 is phenyl.

### Claim 3 (depends on 1)

The polymer conjugate of claim 1, wherein t is from 100 to 300.

### Claim 4 (depends on 1)

The polymer conjugate of claim 1, wherein r is 1, a is 0, and b is 1.

### Claim 5 (depends on 1)

The polymer conjugate of claim 1, wherein Functional group 1 and Functional group 2 are the same or different and independently comprise —COOH, —NH2, —OH, or —B(OH)2.

### Claim 6 (depends on 1)

The polymer conjugate of claim 1 wherein:
Y1 is phenyl;
a is 0;
b is 1;
r is 1;
t is 20 to 300; and
Functional group 2 comprises —OH, —B(OH)2, —COOH, or —NH2

### Claim 7 (depends on 1)

The polymer conjugate of claim 1, wherein at least a portion of the boron atoms comprise 10B.

### Claim 8 (depends on 1)

The polymer conjugate of claim 1, wherein Y1 is an aromatic group comprising at least one 19F, the polymer being detectable by in vivo imaging via 19F NMR spectroscopy when in a patient.

### Claim 9 (depends on 1)

The polymer conjugate of claim 1, wherein Y1 is an aromatic group comprising at least one 18F.

### Claim 10 (depends on 1)

A polymer conjugate of claim 1 and at least one targeting ligand, wherein the boronic acid polymer is coupled to the targeting ligand with at least one reversible linkage with the OH, —B(OH)2, —COOH, or —NH2 of at least one of Functional group 1 or Functional group 2, the at least one targeting ligand comprising a nucleotide, polynucleotide, peptide, polypeptide, protein, full antibody, antibody fragment, polysaccharide, or small molecule.

### Claim 11 (depends on 10)

The polymer conjugate of claim 10, wherein the small molecule comprises transferrin, folic acid, or galactose.

### Claim 12 (depends on 10)

The polymer conjugate of claim 10, wherein the small molecule comprises chemotherapeutics including an epothilone, a camptothecin-based drugs, doxorubicin, taxol, or a nucleic acid.

### Claim 13

A polymer conjugate comprising a boronic acid of formula:
wherein
R3 and R4 are independently (CH2CH2O)t, where t is from 2 to 2000,
X1 is —NH—C(═O)—, —C(═O)—NH—CH2, —C(═O)—NH—, —S—S—, —O—C(═O)— or —C(═O)—O—;
Y1 is an alkylene with a carbon number of at least 1 or is an aromatic group;
Functional group 1 and Functional group 2 are the same or different and independently comprise —OCH3, —OH, —B(OH)2, —COOH, —NH2, or —(X1)—(Y1)—B(OH)2;
r is in a range of from 1 to 1000;
a is 0, 1, 2, or 3; and
b is 1, 2 or 3; and
a polyol polymer having at least one of the following repeating structural units:
wherein
A is an organic moiety of having a structure of:
wherein
the spacer is independently selected from any organic group;
the amino acid is selected from any organic group bearing a free amine and a free carboxylic acid group;
n is a number from 1 to 20; and
Z1 is independently selected from —NH2, —OH, —SH, and —COOH.

### Claim 14 (depends on 13)

The polymer conjugate of claim 13, wherein A is independently:

### Claim 15 (depends on 13)

The polymer conjugate of claim 13, wherein B is
in which q is 1-20; p is 20-200; and L is a leaving group.

### Claim 16 (depends on 13)

The polymer conjugate of claim 13, wherein the structural unit of formula (I) is:

### Claim 17 (depends on 13)

The polymer conjugate of claim 13, wherein the structural unit of formula (II) is:

### Claim 18 (depends on 13)

The polymer conjugate of claim 13, wherein the structural unit of formula (III) is:
in which n is 1-20.

### Claim 19 (depends on 13)

The polymer conjugate of claim 13, wherein the polymer containing a polyol is

### Claim 20 (depends on 13)

The polymer conjugate of claim 13, further comprising a targeting ligand, wherein the boronic acid polymer is coupled to the targeting ligand with at least one reversible linkage with the OH, —B(OH)2, —COOH, or —NH2 of at least one of Functional group 1 or Functional group 2, the targeting ligand comprising at least one a small molecule, protein, protein fragment, peptide, full antibody, antibody fragment, monosaccharide, polysaccharide, nucleotide, or polynucleotide.

### Claim 21 (depends on 20)

The polymer conjugate of claim 20, wherein the targeting ligand is an antibody or antibody fragment against a surface cell receptor.

### Claim 22 (depends on 20)

The polymer conjugate of claim 20, wherein the targeting ligand is folic acid.

### Claim 23 (depends on 20)

The polymer conjugate of claim 20, wherein the targeting ligand is transferrin.

### Claim 24 (depends on 13)

The polymer conjugate of claim 13, further comprising a therapeutic agent, wherein the boronic acid polymer is coupled to the therapeutic agent with at least one reversible linkage with the OH, —B(OH)2, —COOH, or —NH2 of at least one of Functional group 1 or Functional group 2

### Claim 25 (depends on 25)

The polymer conjugate of claim 25, wherein the therapeutic agent comprises at least one of a chemotherapeutic or a nucleic acid.

### Claim 26 (depends on 25)

The polymer conjugate of claim 25, wherein the therapeutic agent comprises camptothecin, doxorubicin, or taxol.
